Cytokinetics, Inc. CEO Robert Blum has maintained since the company reported positive topline Phase III results for the cardiac myosin inhibitor aficamten in obstructive hypertrophic cardiomyopathy (oHCM) in December that it is capable of commercializing the drug on its own. But even without a deal announcement in the ensuing months, including after it presented detailed SEQUOIA-HCM results earlier this month, investors have held out hope that a big pharma would step up to buy Cytokinetics in a multibillion-dollar deal.
Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan
Company’s Stock Plunged In Absence Of M&A Deal
Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.
More from Financing
More from Business
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.